Wednesday, July 22, 2026
← Back to archivePolicy
Policy•STAT News•Jul 22, 2026
Opinion: STAT+: Hospitals’ AI may be drifting. Who’s watching?
background ▾
- •Hospitals are deploying AI across critical clinical workflows without proportionate safety monitoring infrastructure, creating potential patient safety and liability risks.
- •Traditional device approval processes (6+ months, quarterly reviews) are misaligned with AI's need for continuous monitoring and model drift detection.
Policy•STAT News•Jul 22, 2026
As Maui recovers from devastating fires, a study offers vision for new rural health model
background ▾
- •The study has evolved from a pure research project into critical health infrastructure serving an underserved rural population with physician and nursing shortages, demonstrating a potential new model for rural health delivery in disaster-affected areas.
University of Hawai'i
→ Read original articlePolicy•Endpoints News•Jul 22, 2026
Trump pledges new tariffs on generic drugs not made in the US
background ▾
- •Trump proposes up to 200% tariffs on imported generic drugs as leverage to incentivize US domestic manufacturing
- •This policy could fundamentally disrupt the generic drug supply chain, which currently depends heavily on international manufacturing, particularly from India and China
- •Key uncertainties include implementation timeline, specific tariff rates for different drug categories, whether existing drugs are grandfathered, and potential retaliatory trade actions from other countries
Policy•STAT News•Jul 21, 2026
Trump administration says it’s deferring $1B in Medicaid payments to California and Minnesota
background ▾
- •Federal Medicaid payment deferrals now exceed $2.3 billion across multiple states in 2025, creating significant cash flow disruption for state health programs and potentially affecting patient access to services.
- •CMS has not provided detailed fraud evidence or calculation methodologies to states, undermining the credibility of the action and creating legal and operational uncertainty for Medicaid administrators.
- •Watch for state legal challenges, Congressional investigations, and whether other Democratic-led states face similar deferrals; monitor impact on Medicaid managed care plans and pharmacy networks dependent on timely state reimbursements.
Policy•Endpoints News•Jul 21, 2026
Indian generic drugmaker gets FDA warning over clinical study consent
background ▾
- •FDA issued a warning letter to Alembic Pharmaceuticals for informed consent violations in a clinical study, indicating serious GCP/regulatory compliance lapses
- •The enforcement action reflects heightened FDA oversight of clinical trial conduct at international generic manufacturers
- •Alembic will likely face mandatory corrective action requirements and potential delays in clinical development programs pending FDA resolution
Alembic Pharmaceuticals
→ Read original articleMarket Access
Market Access•Fierce Biotech•Jul 22, 2026
‘We’re moving quickly’: Startup bags rare disease drug as Thiel-backed CEO eyes $50M fundraise
background ▾
- •Ashlins has secured an undisclosed rare disease indication for interferon alpha-2b and scheduled a pre-IND meeting with FDA, positioning the company to pursue formal approval for a previously unmet patient population abandoned after Merck's 2022 discontinuation.
- •The $50 million Series A fundraise (targeting October) is intended to fund the interferon program through FDA approval plus pipeline expansion, representing substantial capital deployment for a five-person startup with only $1.7 million raised to date.
- •Watch for FDA pre-IND meeting outcomes in August and the Series A funding close in Q4 2024; commercialization strategy and competitive landscape for interferon alpha-2b in the identified rare disease indication will clarify feasibility.
Ashlins PharmaceuticalsLee's PharmaceuticalMerck & Co.interferon alpha-2bIntron A
→ Read original articleMarket Access•Fierce Biotech•Jul 21, 2026
‘We’ve been looking for a novel approach’: Why Novartis CEO ended ADC holdout for $1.5B Myricx deal
background ▾
- •Novartis ended its multi-year ADC holdout by acquiring Myricx for $1.1B upfront, representing a strategic validation of novel payload technologies over traditional approaches
- •Myricx's NMT-targeting platform offers a mechanistically differentiated approach addressing resistance and toxicity limitations of dominant ADC payloads (topo-1 inhibitors and MMAE-based tubulin inhibitors)
- •Watch for clinical data from Myricx's B7-H3 and HER2-targeting ADCs and whether Novartis expands the NMT payload to additional targets and delivery modalities
NovartisMyricx BioAstraZenecaEnhertuPadcev
→ Read original articleMarket Access•Fierce Biotech•Jul 21, 2026
Jupiter enters psychedelics space with $100M deal for PharmAla's MDMA drug
background ▾
- •Jupiter acquired U.S. rights to ALA-002 (non-racemic MDMA) with $100M deal value structure including $20M FDA approval milestone, signaling continued industry interest in psychedelic therapeutics despite recent setbacks
- •ALA-002 already embedded in government-sponsored Veterans Affairs and Defense Health Agency clinical trials, potentially de-risking development timeline and providing early efficacy signals
- •Watch for: ALA-002 phase 3 advancement timing, FDA regulatory pathway clarification post-Lykos rejection, and whether government support translates to accelerated development or regulatory approval
Jupiter NeurosciencesPharmAla BiotechLykos TherapeuticsALA-002jotrolMDMA
→ Read original articleMarket Access•Endpoints News•Jul 22, 2026
Vertex was only bidder for Crinetics in year's second-highest M&A premium
background ▾
- •Vertex was the only bidder for Crinetics despite offering a top-tier acquisition premium, suggesting either limited strategic fit for competitors or Crinetics' constrained alternatives
- •The deal ranks as the second-highest premium M&A transaction in biopharma in 2024, indicating significant integration costs or perceived synergy value for Vertex
- •Monitor Vertex's integration execution and how Crinetics' pipeline assets (particularly late-stage endocrinology programs) perform post-acquisition in trial and commercial settings
Vertex PharmaceuticalsCrinetics Pharmaceuticals
→ Read original articleMarket Access•STAT News•Jul 22, 2026
Opinion: STAT+: I’m a cardiologist. I’m not sure the new cholesterol drug enlicitide is a game-changer
background ▾
- •Enlicitide is the first oral PCSK9 inhibitor approved by FDA, representing a formulation innovation that removes injection burden from a major drug class
- •Clinical utility remains uncertain despite approval; key unknowns include actual patient adherence improvement, comparative efficacy versus injectables, and which cardiovascular risk populations benefit most
- •Payer coverage, pricing strategy, and real-world adoption rates will determine whether enlicitide captures meaningful market share against established injectable PCSK9 inhibitors and other lipid-lowering therapies
MerckenlicitideLipfendra
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•Jul 21, 2026
Agios says adios to sickle cell program over lackluster phase 2 data
background ▾
- •Tebapivat phase 2 failed to separate from placebo on primary hemoglobin response endpoint (29-47% vs 33% placebo), eliminating the competitive advantage of once-daily dosing
- •Agios now relies solely on Pyrukynd's November 1 FDA decision in SCD, after canceling tebapivat in LR-MDS just two months prior, raising questions about pipeline robustness
- •Novo Nordisk's etavopivat demonstrates superior efficacy (48.7% response at Week 24 in phase 3), establishing a higher bar for PK activators in SCD that Agios failed to meet
Agios PharmaceuticalsNovo NordisktebapivatPyrukyndetavopivat
→ Read original articleClinical Trials•Fierce Biotech•Jul 21, 2026
Indian generics maker Lupin seeds US spinout Kaveri with cash, clinical-phase cancer assets
background ▾
- •Lupin has licensed two clinical-stage oncology assets (PRMT5 and SOS1 inhibitors) to newly formed Kaveri Therapeutics, retaining 82.2% equity and signaling a shift from in-house development to asset spinning to unlock value
- •LNP7457 enters a crowded PRMT5 space with BMS in phase 2/3 and multiple competitors active, while LNP8701 faces lower competition but recent SOS1 setbacks including BMS terminating a phase 1 trial
- •Monitor Kaveri's ability to secure external funding and deliver phase 2 data for both assets, particularly given earlier-stage negative signals in the SOS1 pathway
LupinKaveri TherapeuticsAstraZenecaLNP7457LNP8701BAY3498264
→ Read original articleClinical Trials•Endpoints News•Jul 21, 2026
Gilead and Merck provide HIV data; Dimension Capital announces $800M fund
background ▾
- •Gilead and Merck are advancing a once-weekly oral HIV regimen to Phase 3 data presentation stage, potentially addressing treatment adherence and convenience.
- •Full trial results and endpoints are not disclosed in this announcement, limiting ability to assess clinical significance or market differentiation.
Gilead SciencesMerck
→ Read original articleClinical Trials•Fierce Biotech•Jul 21, 2026
Novartis drops phase 2 radioligand therapy, but CEO’s commitment to modality ‘unchanged’
background ▾
- •Lu-NeoB failed to advance from early clinical testing due to efficacy shortfall, not safety concerns, marking a notable setback in Novartis's RLT pipeline expansion.
- •CEO explicitly confirmed RLT modality commitment remains unchanged and company maintains multiple RLT candidates in active development across PSMA, SSTR, DLL3, HER2, and FAP targets.
- •Watch whether additional RLT candidates encounter similar efficacy challenges and how Ac-PSMA-617 (late-stage PSMA RLT for prostate cancer) progresses as the near-term flagship candidate.
NovartisMyricx BioLu-NeoBLutetium-NeoBPluvicto
→ Read original article